Barrington analyst Kevin Steinke raised the firm’s price target on Cross Country Healthcare to $45 from $41 and keeps an Outperform rating on the shares. The analyst notes the company’s Q3/2022 results exceed recently increased guidance. The demand environment remains favorable due to the extremely tight healthcare labor market, Steinke adds, pointing out that growth also continues to benefit from the significant investments that Cross Country has made in recruiter productivity and capacity.
Published first on TheFly
Read More on CCRN: